Education
About Us
Working with TipRanks
Follow Us
Kamada (KMDA)
NASDAQ:KMDA
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.09Last Year’s EPS
0.02Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, a significant increase in adjusted EBITDA, and successful diversification of the portfolio. However, there were concerns about the flat sales of CYTOGAM and potential indirect impacts of tariffs and global trade changes. The high tax rate also raised questions, but the overall outlook remains positive with reiterated guidance and ongoing expansion efforts.Company Guidance
During Kamada's Q1 2025 earnings call, the company reported strong financial results and reiterated its annual guidance. Total revenues for the first quarter increased by approximately 17% year-over-year to $44 million, driven by higher sales of GLASSIA, KAMRAB in ex-U.S. markets, and VARIZIG, along with GLASSIA royalties income. Adjusted EBITDA rose by 54% to $11.6 million. Kamada anticipates annual revenues of $178 million to $182 million and adjusted EBITDA of $38 million to $42 million for 2025, reflecting growth of 12% and 17% respectively over 2024. The company continues to focus on its four-pillar growth strategy, which includes organic commercial growth, business development, plasma collection expansion, and advancing its Phase 3 inhaled Alpha-1 program. Kamada also launched a comprehensive post-marketing research program for CYTOGAM, aiming to enhance the management of CMV disease, and plans to introduce additional biosimilars to boost its distribution business.Strong Revenue Growth
Total revenues for Q1 2025 were $44 million, marking an approximately 17% increase year-over-year.
Significant Increase in Adjusted EBITDA
Adjusted EBITDA reached $11.6 million, representing a 54% increase over the previous year.
Diversified Portfolio Performance
Growth was driven by increased sales of GLASSIA and KAMRAB in ex-U.S. markets, as well as VARIZIG sales and GLASSIA royalties income.
Guidance for 2025
The company is reiterating its 2025 annual guidance of $178 million to $182 million in revenues and $38 million to $42 million of adjusted EBITDA.
Successful Launch of Biosimilars
Following the first biosimilar product launch in Israel, two additional biosimilars are expected to launch later this year.
Expansion of Plasma Collection
The opening of a new plasma collection center in San Antonio, Texas, which supports over 50 donor beds, is expected to contribute significantly to annual revenues.
Ongoing Phase 3 Clinical Trial
Progress in the pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy is on track with an interim futility analysis expected by the end of 2025.
KMDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KMDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $6.89 | $7.05 | +2.32% |
Mar 05, 2025 | $6.42 | $6.90 | +7.48% |
Nov 13, 2024 | $6.10 | $5.86 | -3.93% |
Aug 14, 2024 | $5.40 | $5.18 | -4.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kamada (KMDA) report earnings?
Kamada (KMDA) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Kamada (KMDA) earnings time?
Kamada (KMDA) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KMDA EPS forecast?
KMDA EPS forecast for the fiscal quarter 2025 (Q2) is 0.09.